Pharmaceutical Industry

SOSCLEANROOM | PHARMACEUTICAL MANUFACTURING & CONTAMINATION CONTROL

Protect Product Quality by Controlling Every Contamination Pathway.

A pharmaceutical cleanroom technical reference for sterile and nonsterile drug manufacturing: cGMP requirements, EU GMP Annex 1, contamination control strategy, disinfectant qualification, material transfer, gowning, environmental monitoring, equipment cleaning validation, and responsible selection of wipers, swabs, gloves and cleaning chemistry.

Explore the Technical Guide ↓ Visit the Technical Vault →

The essential principle

A pharmaceutical cleanroom is a controlled process, not a clean-looking room.

In drug manufacturing, contamination can originate in the facility, raw materials, utilities, equipment, operators, process interventions or the cleaning tools themselves. It may appear as living microorganisms, endotoxins, fibers, airborne particles, glass fragments, active pharmaceutical ingredient (API) carryover, cleaning-agent residue or mix-ups in components. Passing an airborne-particle classification alone does not demonstrate that drug product, equipment or personnel are adequately controlled.

Reliable control combines suitable facility design, prevention, qualified people and suppliers, approved procedures, scientifically defensible monitoring, meaningful investigations and ongoing improvement. For sterile products, the European Commission describes this coordinated system as a Contamination Control Strategy (CCS); FDA cGMP regulations similarly demand written and implemented controls against contamination.

01 | Prevent

Design out avoidable contamination

Use appropriate room segregation, cleanable equipment, qualified utilities, closed transfers and barrier technology where justified. An engineered control is generally stronger than relying on repeated operator correction.

02 | Standardize

Reduce execution variability

Control the approved chemicals, swabs, wipers, gloves, packaging, application sequence, contact time, change frequency and post-cleaning protection.

03 | Verify

Use evidence that answers the right question

Particle counts address airborne particles. Microbiological samples address viable contamination. Cleaning-validation assays evaluate residues. None is a substitute for the others.

04 | Improve

Learn from trends and deviations

Connect excursions, changes, maintenance events, investigation findings, CAPA and supplier data to the actual process risk and the site quality system.

Scope matters

This guide covers US and EU manufacturing concepts and provides separate context for hospital and pharmacy compounding. Whether a particular rule applies depends on the drug, dosage form, manufacturing process, site, jurisdiction and approved quality system. Do not apply sterile-fill requirements indiscriminately to every nonsterile operation.

Different processes require different controls

Where cleanrooms and cleanroom consumables fit across pharmaceutical manufacturing.

The appropriate environmental protection is determined by what is exposed, when it is exposed, and what contamination would do to the product. An aseptically filled injectable, a terminally sterilized preparation, a solid oral dosage form and an active pharmaceutical ingredient can demand very different facilities, cleaning methods and monitoring.

Sterile fill-finish

Aseptic filling and open sterile operations

Open sterile product, exposed sterile components and aseptic connections require particularly rigorous protection. The program may include Grade A critical zones, background areas, isolators or RABS, qualified interventions and microbiological monitoring.

Sterile finished dosage forms

Terminal sterilization processes

Where a qualified terminal sterilization process is used, pre-sterilization bioburden, endotoxin and particulate controls still matter. The needed room grades depend on process stage and product risk; terminal sterilization is not a substitute for poor upstream control.

Nonsterile drug products

Solid oral doses, liquids, creams and topicals

Product mix-ups, API carryover, dust, moisture and objectionable microorganisms may dominate. A facility can require robust zoning and validated equipment cleaning without every operation being performed in an ISO-classified room.

Active pharmaceutical ingredients

API manufacturing and shared process equipment

Control cross-contamination, cleaning-agent residues, intermediate/product carryover, equipment changeovers and appropriate area segregation under applicable API GMP requirements.

Biological drug products

Biologics, vaccines and sensitive intermediates

Bioburden, product-contact materials, aseptic additions, endotoxin and product-specific residue concerns can be critical. EU Annex 2 and, where applicable, ATMP-specific guidance have their own scopes.

Quality control

QC, microbiology and sampling laboratories

Maintain reliable sampling technique, sample traceability, suitable background controls, swab recovery, handling of test articles and segregation between analytical and manufacturing activity.

Pharmacies and healthcare

USP sterile and hazardous compounding

USP <797> concerns compounded sterile preparations and USP <800> hazardous-drug handling in healthcare settings. These chapters are important but should not be substituted for manufacturing cGMP rules.

Related industry-specific resource: Biotechnology Industry contamination-control guide.

Regulatory and technical landscape

Which requirements apply — and what question each one answers?

Start with the applicable regulatory scope, licensed operations and site quality procedures. The references below have different legal status and objectives: regulations, agency guidance, compendial chapters and consensus ISO standards are not interchangeable. In the EU, Annex 1 is the sterile-medicinal-products guidance; in the US, 21 CFR Part 211 contains binding drug-product cGMP requirements, while FDA guidance explains agency recommendations.

Reference	What it addresses	What it does not automatically establish
21 CFR 211.42	Drug-manufacturing premises, material flow and aseptic-processing environmental design controls.	One universal ISO room class for every pharmaceutical operation.
21 CFR 211.67	Equipment cleaning/maintenance procedures, schedules, inspection and records.	That visually clean equipment has met a residue limit or that sterilization is unnecessary.
21 CFR 211.113	Written controls against objectionable microorganisms and additional aseptic/sterilization validation for sterile products.	That the same microbiological method or disinfection schedule applies in all sites.
FDA aseptic processing guidance (2004)	FDA recommendations for sterile drug and biological products manufactured aseptically.	A replacement for the actual cGMP regulations or a binding requirement by itself.
EU GMP Annex 1 (2022; fully applicable 2024)	Risk-based CCS, premises, operations, personnel, utilities, disinfection, aseptic processing, monitoring.	That EU Grade A is universally equivalent to any item marketed as ISO 5-compatible.
EU GMP Annex 15	Qualification and validation, including product-contact equipment cleaning validation.	A single universal numeric acceptance limit across products and equipment.
ICH Q9(R1) / FDA (2023)	Tools and principles for pharmaceutical quality risk management.	Permission to disregard explicit regulations or documented quality decisions.
ISO 14644-1:2015	Airborne particle classification of cleanrooms and associated controlled environments.	Microbial sterility, finished-product acceptability or residue cleanliness.
ISO 14644-5:2025	Operations Control Program for personnel, materials, cleaning, maintenance and monitoring.	A drug-specific GMP approval or product sterility certificate.
ISO 14644-18:2023	Evaluation of consumables for cleanroom use and relevant contamination attributes.	Functional disinfectant efficacy, a chemical PPE rating or a universal product ISO certificate.
USP <797>	Minimum standards for compounded sterile preparations in its defined scope.	Manufacturing approval for commercially produced sterile drugs.
USP <800>	Hazardous-drug handling and exposure control in healthcare settings.	A generic cleaning method for every pharmaceutical manufacturing area.

Do not use "ISO class" as a consumable certification

An ISO air classification describes measured airborne-particle concentrations in an environment. A wiper, glove or swab can have manufacturer recommendations for particular cleanrooms, but its suitability must still be assessed for the specific process, contamination risk, sterility, packaging and chemistry. ISO 14644-18 explains the assessment framework.

Define what must not enter the product

Six contamination pathways that require different controls and tests.

Hazard	Typical sources	Potential product impact	Appropriate evidence/control
Viable microorganisms	People, transfer surfaces, wet equipment, inadequate sanitization, utilities.	Microbial contamination and potential sterility failure or spoilage.	Aseptic process controls, bioburden/viable monitoring, validated disinfection and investigations.
Bacterial endotoxin / pyrogen	Gram-negative bacterial contamination of water, materials and product-contact systems; biofilm.	Pyrogenic response in vulnerable parenteral applications.	Qualified water systems, bioburden control and validated endotoxin testing; disinfection alone is not depyrogenation.
Nonviable particles / fibers	Air systems, garment shedding, packaging, worn equipment, wipes, glass.	Foreign matter and potential contamination of exposed product or sterile components.	Air monitoring, material suitability assessment, visual/particulate testing and protected transfers.
API / product carryover	Shared vessels, seals, transfer lines, valves and difficult-to-clean geometry.	Cross-contamination and unacceptable exposure to other products.	Scientifically justified residue limits, cleaning validation, sampling recovery and changeover control.
Cleaning agents / chemical residue	Incomplete rinsing, incompatible disinfectants, wiper/swab extractables, concentrated solutions.	Interference with assays, material interactions, quality defects or carryover.	Validated application/rinsing, chemical assays, compatibility testing and approved concentrations.
Mix-ups and traceability failures	Uncontrolled labels, mixed batches, incorrect lot/grade, improper staging.	Identity/strength errors and inability to reconstruct a deviation.	Material flow, lot traceability, line clearance, clear labeling and accurate records.

The practical lesson: a clean air particle trend cannot prove freedom from microorganisms, a microbial sample cannot quantify API carryover, and a "low-lint" claim cannot establish chemical compatibility. Match the test and the control to the failure mode.

Understand the environmental hierarchy

EU GMP Grade A, B, C and D are process-dependent — not a universal product ranking.

EU GMP Annex 1 provides examples of operations and environmental grades for sterile manufacturing. The grade attached to a step depends on the actual configuration, barrier system and exposure pathway. A drug-manufacturing program must not assign grades to all pharmaceutical activities solely from a general marketing chart.

Grade / situation	Typical application under Annex 1	Important qualification
Grade A	Critical zones for exposed sterile product and components, aseptic filling, open aseptic manipulations and some aseptic connections.	First-air protection and intervention minimization matter; isolators and RABS change background requirements.
Grade B	Commonly the supporting background for Grade A aseptic processing that is not protected by an isolator.	The background for an isolator can differ and must be justified under Annex 1.
Grade C	Lower-risk preparation stages, including certain solution preparation and handling operations.	Not an automatic default for every pharmaceutical laboratory or bulk drug step.
Grade D	Some cleaned-equipment, component-handling and supporting preparation activities.	In-operation particle classification is not predetermined in Annex 1 for Grade D; the site sets limits as justified.
Nonsterile controlled area	Risk-based containment, cross-contamination prevention, cleanable surfaces and documented material flow.	There may be no specific ISO air class if the applicable process and quality requirements do not demand one.

Annex 1 also distinguishes classification (demonstrating environmental capability) from routine environmental and process monitoring (showing continued control). Gowning, airlocks, material transfer and cleaning must fit the actual operation. See Annex 1 sections 4, 7, 8 and 9.

Coordinate all contamination controls

Build the Contamination Control Strategy around critical control points.

For EU sterile manufacturing, Annex 1 calls for a facility-wide CCS that integrates process design and controls, assesses their combined effectiveness, and is actively reviewed. A CCS is not merely a cleaning schedule or a list of disinfectants. It maps what could contaminate the product, where the pathway exists, which prevention mechanism blocks it, how that control is verified and who acts on failure.

Facility and flow

Airflow, room design and segregation

Map exposed-product locations, pressure relationships, door interlocks, material staging, maintenance access and cleaning accessibility.

Utilities

Water, gases and environmental services

Qualify and monitor high-risk utilities based on product contact, bioburden, endotoxin, chemical attributes and process needs.

People

Aseptic behavior and qualification

Control gowning, glove sanitization, movement, intervention technique, training, periodic assessment and response to observed failures.

Suppliers

Consumables, sterilization and documentation

Approve key suppliers, packaging configurations, sterilization evidence, certificates, critical material attributes and authorized substitutions.

Surface treatment

Cleaning, disinfecting and sporicidal strategy

Use approved chemistry, substrate and method combinations; demonstrate contact time, surface compatibility and required residue management.

Monitoring

Air, surface, people and process evidence

Choose sampling locations and triggers from risk, review trends, investigate events and link results to product impact.

Change control

Prevent unqualified substitutions

Assess new wipers, new glove materials, different cleaners, new packaging, equipment work and process changes before introduction.

CAPA

Make deviations reduce future risk

Investigate root cause and affected lots; document corrective action, effectiveness checks and CCS updates.

What a strong CCS says about a wiper

Not simply "use sterile wiper." It identifies the exact purpose and zone, suitable material and sterility, packaging transfer and expiry, wetting agent and compatibility, disposal behavior, qualification evidence, and controlled alternate part numbers.

Primary source: EU GMP Annex 1 sections 2.2–2.6.

Stop using important terms interchangeably

Cleaning, disinfection, sporicidal treatment and sterilization solve different problems.

Process	Main purpose	Common misunderstanding to avoid
Cleaning	Physically remove soil, residues, particulates and material that could interfere with subsequent treatment.	A disinfectant generally does not replace effective soil removal; the process must be suitable for the surface.
Routine disinfection	Reduce viable microorganisms by a product- and method-specific action.	A surface "sprayed with alcohol" is not proven disinfected unless the validated or approved method meets its conditions.
Sporicidal disinfection	Address resistant bacterial spores using an agent with appropriate efficacy and application conditions.	70% IPA is not reliably sporicidal; "sporicidal" should not be inferred from oxidizer concentration alone.
Sterilization	Use a validated process intended to render an item sterile within defined process and assurance parameters.	Wiping with sterile IPA, a sporicide or a sterile wiper does not sterilize equipment.
Depyrogenation	Reduce or remove pyrogens/endotoxins under appropriately validated conditions.	Disinfection or sterile packaging does not establish removal of bacterial endotoxin.
Product-contact cleaning validation	Demonstrate acceptable removal of carryover residues from equipment under defined conditions.	This is different from validating a room-surface disinfectant for microbial efficacy.

For sterile facilities, Annex 1 §4.33 directs sites to clean before disinfecting, address disinfectant residues, use more than one appropriate disinfectant type and periodically use a sporicide. Section 4.34 calls for validation under actual use conditions; section 4.35 addresses sterility requirements for disinfectants and detergents used in Grade A/B areas.

A rotation calendar is not a validation report

A program that uses one routine disinfectant plus a qualified periodic sporicide may be rational; the required combination, application frequency and surface coverage must follow the site CCS and effective instructions. Neither "alternate chemicals every day" nor "one solution works everywhere" is a universal GMP rule. Annex 1 paragraphs 4.33–4.35.

Choose chemistry by task and label

How sterile alcohol, hydrogen peroxide, sporicides and detergents fit into a controlled program.

Chemistry / format	Potential use	Critical qualification questions
Sterile 70% IPA or ethanol	Approved routine alcohol wipe-down of compatible surfaces and certain controlled material transfers.	Is sterile presentation needed? What are the alcohol/water grades? Is the claimed disinfection use supported? Is the surface compatible? IPA is flammable and not sporicidal.
Hydrogen peroxide formulations	Microbial control or periodic treatment where the exact product efficacy is supported.	Does the actual product carry an appropriate sporicidal claim? What contact time, concentration, surface compatibility and residue handling apply?
Quaternary ammonium / phenolic chemistry	Specific routine disinfecting tasks where a validated program permits them.	Surface compatibility, efficacy against the site flora, residue formation, operator exposure and required follow-up cleaning.
Peracetic-acid or chlorine-based sporicides	Specified spore-control applications if label, safety and validation support them.	Corrosion, material degradation, odor, ventilation, wet contact time and potential incompatibility with other cleaners.
Aqueous detergents / formulated cleaners	Removal of soils, films, oils and process residues prior to further treatment.	Detergency versus residue risk, water grade, cleanability, rinsing, material compatibility and microbial control.
Pre-wetted sterile wipers	Controlled delivery of a defined cleaner or solvent by the manufacturer.	Does the specific SKU match required chemistry, water grade, wiper substrate, sterility and packaging configuration?

Use the specific current product label and safety data sheet for approved applications, wet contact times, dilution, PPE, warnings, and material compatibility. For EPA-registered disinfectants, match the relevant claim and directions; a product name or family description is not a substitute for the applicable label. Avoid mixing chemical agents or improvising disinfection sequences.

Explore related education: Sporicides and Proper Use and Solutions Matched to Wipers and Swabs.

Water grade is an engineering decision

DI water, USP Purified Water and WFI are not interchangeable labels.

For pharmaceutical manufacturing, water is a potential source of ionic residue, organic contaminants, microorganisms and endotoxin. The needed specification is driven by the intended use, direct or indirect product contact, pharmacopoeial requirements and approved quality system. "0.2-micron filtered" does not automatically mean sterile, and "WFI" does not by itself describe a sterile, ready-to-use packaged solution.

Water designation	How to interpret the term	Selection implication
Deionized (DI) water	Describes removal of ions by a treatment approach; it does not by itself prove compendial water specifications, sterility or endotoxin control.	May be acceptable for general cleaning if qualified for the task; do not assume it is equivalent to USP Purified Water or WFI.
USP Purified Water (PW)	A pharmacopoeial water grade with specified chemical and microbial control expectations when applied to a qualified system.	May be selected for appropriate formulations, cleaning or rinsing per the approved process and current compendial requirements.
Water for Injection (WFI)	A higher-purity pharmacopoeial grade selected for relevant parenteral applications and other defined uses, including stringent endotoxin control.	Needed where required by process/compendial standards; does not imply packaged product sterility without suitable manufacture and presentation.
Sterile packaged water or solution	Sterile status is a separate product attribute established by appropriate validated processes and packaging.	Verify sterility, package configuration, in-use period, expiry and documentation for the actual SKU.

Annex 1 section 6 addresses qualification, monitoring, biofilm prevention and sampling of pharmaceutical water systems. For a pre-wetted wiper, review the actual ingredient specification: for example, SOScleanroom lists TX3280 with 30% WFI and TX3213 with 30% DI water as different sterile IPA/wiper configurations. Neither is universally preferred absent a process specification.

Translate requirements into repeatable handling

An operator-friendly method framework for surfaces, corners, walls and equipment.

The following is a training-planning framework, not a substitute for approved site SOPs or validated cleaning and disinfection methods. Critical details—including wipe folding, force, direction, whether direct spraying is permitted, wetness, contact time, change interval and rinse—must be defined for the specific zone, chemistry and equipment.

Step 01

Confirm the room and process state

Identify the grade or zone, batch status, exposure risk and whether cleaning is routine, after maintenance, after a spill or part of product-changeover release.

Step 02

Inspect approved supplies

Check chemical identification, lot, expiry, prepared-solution hold time, sterile barrier integrity when required, and correct swab/wiper/mop configuration.

Step 03

Prepare controlled entry

Follow documented material transfer, removal of outer corrugate where required, appropriate gowning and tool staging; avoid bringing uncontrolled packaging into critical zones.

Step 04

Remove soil with the right tool

Work in the defined order, commonly cleaner-to-dirtier and higher-to-lower for appropriate surfaces. Use the approved substrate and amount of solution; prevent already-used wipe faces contacting cleaned areas.

Step 05

Address seams and difficult geometry

Use approved swabs or small-area tools for joints, corners and gasket interfaces where a flat wiper may miss contact. Confirm that a swab head and handle tolerate the chemistry.

Step 06

Execute disinfection as validated

Apply the correct solution in the appropriate manner, maintain required wet contact time, protect critical airflow and avoid aerosolizing chemistry toward exposed product.

Step 07

Remove residues and protect cleanliness

If required, perform the approved follow-up wipe or rinse after the specified dwell. Follow defined drying, assembly, storage and clean-hold conditions.

Step 08

Document and release

Record zone/equipment, chemistry, operator, time, lot, observations, exceptions and required quality review or verification before product exposure resumes.

Wiping and mopping techniques are not universally interchangeable

A process for cleaning a floor, stainless-steel cart, isolator interior, glass vial contact surface or electronic panel may use different agents and tools. Wall and floor mop covers need defined change triggers, area boundaries and disposal paths. Specialized optical, electronic and oxygen-service surfaces require additional approval. Do not transpose a generalized cleaning poster into a sterile drug process without evaluating its risks.

Operator training resource: Training Material and How-To Guides.

The most overlooked contamination pathway

Control gowning, interventions and the material-transfer boundary.

Personnel and incoming materials routinely present more exposure opportunities than the storage shelf where the product was purchased. Even a sterile glove or wiper can be compromised after inappropriate handling. For sterile manufacturing, facility design and operator technique must protect the critical zone throughout interventions and transfer.

Gowning

Fit, sequence and integrity

Use the correct garment system and documented donning steps; inspect for damage and perform required gowning qualification. The right garment depends on area, activity and product risk.

Gloves

Sterile status plus protection

Choose cleanroom-compatible gloves with the required sterile status, dexterity, cuff fit and chemical resistance. Define sanitization and change triggers; verify glove performance when exposed to routine disinfectants.

Touch discipline

Protect the critical path

A glove that contacts a phone, door, outer package or contaminated equipment may require sanitization or replacement before critical work. Facility rules should make these triggers explicit.

Material transfer

Control packaging at each boundary

Decide which bags are removed at what grade, how outer surfaces are disinfected and how sterile barriers are protected. A double-bagged package assists transfer but is not an independent assurance of aseptic entry.

Barriers

Minimize and qualify interventions

Use isolators, RABS and closed systems when appropriate; document glove-port integrity, allowed interventions, airflow protection and response to a compromised barrier.

Maintenance

Treat intrusions as process events

After HVAC work, seal replacement, equipment access or other disturbances, protect exposed materials and follow approved restoration, cleaning and requalification triggers.

For side-by-side selection of disposable and reusable attire, see Laundered vs. Disposable Cleanroom Garments; for fit, see Glove Sizing and Proper Fit Guide.

Evidence must be interpreted together

Environmental monitoring, surface checks and cleaning verification ask different questions.

Method	What it measures or supports	What it cannot prove by itself
Nonviable particle monitoring	Particle concentration and environmental trends during relevant states and operations.	Microbial sterility, API carryover or disinfection efficacy.
Viable air and settle sampling	Culturable microorganisms captured under defined sampling conditions.	That unmonitored surfaces or product are sterile; recovery depends on method and conditions.
Contact plates, swabs and personnel checks	Local surface contamination and personnel gowning performance where used.	A universal evaluation of every surface or material without suitable neutralization and recovery.
Bioburden and endotoxin analysis	Selected microbial/endotoxin attributes of water, process materials and samples.	That all residual cleaning agents or chemical carryover are absent.
TOC, HPLC and related chemistry assays	Analytical evidence for defined residues and cleaning-validation methods.	TOC is nonspecific; low TOC alone does not establish absence of a specific API.
Visual inspection	Gross residue, fibers, spots, physical damage and execution problems.	Analytical compliance with sufficiently low chemical carryover acceptance limits.
Trend and deviation review	Signals of drift, recurring flora, personnel issues and relationship between changes and results.	Root cause without a documented investigation and impact assessment.

In EU sterile manufacturing, classification, routine monitoring and aseptic process simulations (APS) are distinct activities. Sampling locations, alert/action levels, response and data review belong to the CCS and process-specific program. Regulatory minimums must be distinguished from local tighter targets and sampling recovery limits. Annex 1 section 9.

Cleaning validation is a manufacturing discipline

How to prove that shared equipment cleaning consistently controls residue carryover.

For pharmaceutical product-contact equipment, cleaning validation is intended to establish with scientific data that the cleaning procedure consistently reduces relevant contamination to acceptable, predefined levels. It should address the product and equipment train, worst-case residue, cleaning-agent residues, sampling recovery, dirty/clean hold times and method capability. Annex 15 section 10 describes this approach; the FDA also publishes a longstanding inspection guide.

01 | Define scope

Map products and contact surfaces

Identify equipment trains, previous/next product combinations, seals, difficult-to-clean features, product changeovers and manual versus automated cleaning steps.

02 | Set limits

Justify acceptance criteria

Use applicable toxicological/health-based exposure concepts and process risk; consider carryover from multiple pieces of equipment and limits for cleaning agents.

03 | Challenge worst cases

Select representative conditions

Consider product solubility, potency, cleanability, geometry, campaign length, residue drying and maximum allowable time before cleaning.

04 | Choose sampling

Use swab and/or rinse with purpose

Direct swabbing can target localized residues; rinse can access enclosed systems but may miss insoluble or trapped contamination. Neither is inherently appropriate for every system.

05 | Validate recovery

Understand the swab + surface + solvent

Demonstrate recovery from representative surface materials, using the selected swab, diluent, extraction method and analytical procedure. Account for blanks and background.

06 | Verify the assay

Match sensitivity to the risk limit

Assess method specificity, detection and quantitation ability, sample handling, extraction stability and potential swab or detergent interference.

07 | Control hold times

Validate dirty and clean storage conditions

Evaluate the time between manufacture and cleaning, and between cleaning and next use; prevent microbiological proliferation and uncontrolled drying.

08 | Document lifecycle

Protocol, results and change control

Execute and approve the protocol/report, define continuing verification, reassessment after changes, investigation pathways and record retention.

Why Low-TOC swabs help — and what they cannot guarantee

A low-background swab such as Texwipe TX714K helps reduce method blank contribution in TOC-based sampling. It does not by itself validate recovery from stainless steel, gaskets or coated surfaces, demonstrate an API-specific limit, or replace the analytical method and SOP. TOC is a collective carbon measurement; site method qualification determines what it can support.

Four comparisons worth documenting in every sampling protocol

Decision	Why it affects the result	Questions for the protocol
Swab vs. rinse	Sampling mechanism and access change what can be recovered.	Which sites are worst-case? Is residue soluble? Can the swab physically reach the surface?
Swab background vs. assay limit	A high or variable blank can mask low residue levels.	What are blank limits, lot controls, extraction volumes and allowable background?
Recovery factor vs. result	Measured content can underestimate residue remaining on the surface.	Was percent recovery established on this material at relevant levels? How is it handled in the calculation?
Specific assay vs. nonspecific TOC	TOC may reflect multiple organic species rather than one API.	Is the method specific enough for the residue and risk decision? Are cleaning agents an interference?

See EU GMP Annex 15 cleaning validation and FDA Inspection Guide to Cleaning Validation for the underlying principles. The choice of limits and methods belongs to qualified QA, validation and analytical personnel.

Qualify consumables for their actual use

Selection gates for wipers, swabs, gloves, garments, solutions and mops.

The right supply is not simply the most absorbent, cleanest-sounding, or highest-numbered product. Suppliers publish different particle, ion, nonvolatile-residue, sterility, physical and packaging data; your quality program must determine which attributes are critical.

Consumable	Product attributes to review	Common qualification mistake
Dry wipers	Polyester/cellulose/polypropylene content, sealed vs. cut edge, particle/fiber release, absorbency, residues, size, packaging.	Assuming "lint-free" or ISO-compatible marketing language guarantees process cleanliness.
Pre-wetted wipers	Wiper material plus solution concentration, water grade, fluid content, sterility, pouch format and solvent compatibility.	Treating DI-water and WFI-based products as identical or using an unapproved alcohol solution.
Precision cleaning swabs	Head geometry, fabric/foam material, head bond, handle composition, solvent compatibility, particle release.	Using a sampling swab where mechanical cleaning performance is needed or vice versa.
Cleaning-validation swabs	Low background, lot traceability, sampling area, vial/solvent compatibility, desorption and demonstrated recovery.	Assuming a low-TOC certificate establishes validated API or detergent recovery.
Gloves and gowns	Sterility when required, barrier integrity, fit, particle profile, garment interfaces, chemical resistance and packaging.	Using an ordinary cleanroom glove as a substitute for chemically protective PPE.
Disinfectants / cleaning solutions	Identity, efficacy/label, sterile status, chemistry, use concentration, in-use period, surface compatibility and residues.	Confusing sterile formulation with sporicidal effectiveness or ignoring wet contact time.
Mops and large-surface tools	Cover compatibility, wetting, area-change rules, cleaning reach, sterility and cleaning/reuse process.	Using a general janitorial mop system in contamination-sensitive areas.

Procurement control point

Where sterile materials are needed, check the exact SKU rather than assuming the entire product family is sterile. Supplier certificates and sterilization documents support qualification but do not approve the customer’s process by themselves. ISO 14644-18 offers a general consumable-assessment structure.

Verified SOScleanroom catalog examples

Candidate supplies for engineering and purchasing review — not GMP certification.

These are live SOSCleanroom product listings verified during this editorial review. They illustrate meaningful sterile versus nonsterile, dry versus pre-wetted, and cleaning versus analytical sampling choices. Actual suitability requires manufacturer documentation, current SKU specifications, material compatibility and your approved SOP. Availability and pricing can change.

Sterile dry polyester

Texwipe TX3211 SterileWipe LP 9 x 9

Dry sterile polyester cleanroom wiper for an approved cleaning process requiring a sterile applicator. Choose the solution and method separately; verify packaging and process suitability.

Sterile pre-wetted | WFI

Texwipe TX3280 AlphaSat10 12 x 12

Sterile polyester pre-wetted wiper listed with 70% IPA / 30% WFI. Consider when WFI-containing pre-wet chemistry and a larger wipe are documented process needs.

Sterile pre-wetted | DI

Texwipe TX3213 PolySat 9 x 11

Sterile polypropylene wiper pre-wetted with 70% IPA / 30% DI water. Not chemically identical to TX3280; validate material, use zone and water specification.

Sterile 70% IPA solution

Texwipe TX3270 16 oz Sterile 70% IPA

Ready-to-use sterile IPA solution intended for contamination-controlled wipe-downs. Review flammability, desired application method, container configuration and approved contact requirements.

Sterile oxidizing solution

Decon Peroxigen ST 9716 6% H2O2

Sterile hydrogen peroxide formulation; evaluate the actual label claim, contact time, compatibility, PPE and availability before incorporating it into a disinfectant or sporicidal program.

Validation sampling

Texwipe TX714K Low-TOC Sampling Swab

Low-background polyester snap swab intended for TOC-oriented surface sampling. Verify extraction recovery, dilution, blanks and any API-specific assay limits.

Nonsterile cleaning

Texwipe TX1009 AlphaWipe 9 x 9

General-purpose nonsterile polyester wiper for appropriate support-area or equipment tasks. Not a substitute where sterile consumables are specified.

Sterile cleanroom glove

Ansell 93-700 TouchNTuff Sterile Nitrile

Sterile nitrile glove listing for controlled aseptic use. Confirm correct size, chemical protection, gown interface and lot/sterility documentation; customer approval remains necessary.

Nonsterile cleanroom glove

Ansell 93-311 Nitrilite Nitrile

Nonsterile cleanroom glove for an approved nonsterile task. Selecting a glove by its cleanroom class claim alone does not establish aseptic suitability.

Browse complete product families

Category

Sterile Cleanroom Wipers

Compare dry and pre-wetted formats, polymer substrates, handling and packaging requirements.

Category

Cleaning Validation Swabs

Browse dedicated sampling swabs for TOC and other method-based validation needs.

Category

Sterile 70% IPA Solutions

Review concentration, container presentation, sterile processing and shipping constraints.

Category

Sterile Nitrile Gloves

Compare fit, material, packaging and sterile status for qualified gowning programs.

Category

Cleanroom Mopping Systems

Select compatible mop platforms and covers for large-surface cleaning and disinfection.

Category

Sporicidal Disinfectants

Review specific formulations and their currently applicable label and safety requirements.

Build repeatable methods that withstand audits

Six SOP modules for your site quality and contamination-control program.

These modules are planning prompts for quality, microbiology, engineering and operations—not ready-to-use validated operating procedures. Each needs local approval, role assignment, training, applicable regulatory review and effectiveness verification.

Module 01

Pre-operation room and equipment release

Verify room state, prior batch line clearance, environmental status, clean/sterile equipment staging, approved supplies and documentation before exposing product.

Module 02

Material introduction and bag removal

Define entry route, outer-packaging restrictions, disinfected transfer surfaces, sterile-barrier integrity, hold times and deviations at each airlock or pass-through.

Module 03

Routine surface cleaning and disinfection

Specify surfaces, approved chemistry, solution preparation, applicator, number of passes, wet dwell, residue finish, mop/wipe changes and execution record.

Module 04

Product-changeover equipment cleaning

Define dirty-hold limits, disassembly, cleaning parameters, difficult geometry, visual checks, required analytical sampling and quality release.

Module 05

Environmental and personnel monitoring

Define risk-based sites, timing, methods, neutralization, sample handling, limits, trends and escalation—including intervention-related monitoring where applicable.

Module 06

Excursion and recovery

Define how to protect work, stop or segregate processing, identify impacted product, investigate root cause, restore conditions and authorize return to use.

A minimum usable cleaning record

Identity: room, equipment, zone, work order or batch link; applicable SOP revision.
Materials: solution name, concentration, lot, expiry/in-use time, wiper or mop SKU and relevant sterility/packaging status.
Execution: operator, date/time, required sequence and wet-contact-time confirmation if applicable.
Evidence: visual checks, required monitoring/analytical results, deviation references and cleaning status.
Release: required independent verification, quality approval and controlled clean-hold expiration before next use.

The goal is traceable execution—not simply a completed checkbox. FDA data-integrity guidance emphasizes reliable, accurate and risk-managed records. FDA Data Integrity and Compliance With Drug CGMP.

When results drift, diagnose before repeating the same cleaning

Practical investigation map for recurring contamination and residue failures.

Observed problem	Priority investigation questions	Potential next action
Viable recoveries persist after disinfection	Were surfaces pre-cleaned? Did contact time and correct chemistry reach the site? Were sampling neutralizers effective? Are materials or operators reintroducing organisms?	Review disinfection execution, site flora, method validation, cleaning boundaries and transfer paths; investigate product impact.
Particles increase after new wipes or garments	Did substrate, packaging, laundering/sterilization or handling change? Are edges snagging or gloves shedding?	Review supplier change history, particle/fiber data and real-use testing; revert substitutions only with controlled approval.
API residue fails on a shared line	Was worst-case product addressed? Are seals, valves, dead legs or dirty-hold times controlled? Is sampling recovery valid?	Escalate to validation/QA, inspect hard-to-clean locations and assess impacted equipment and product.
High TOC or unexpected blanks	Could the swab, vial, diluent, glove, cleaning agent or sample handling introduce carbon?	Run controlled blanks and recoveries; confirm analytical specificity and current lot documentation.
Disinfectant streaks or surface corrosion	Does formulation leave residues? Was a post-contact rinse skipped? Has repeated chemical exposure damaged coatings or seals?	Confirm label/SDS, review compatibility, inspect representative surfaces and approved finish sequence.
Recurring excursions near pass-throughs	Are bag layers handled correctly? Are containers wet? Are operators touching unclean boundaries?	Observe actual transfers, check airlock operation, evaluate personnel behavior and revise qualified transfer controls.
Deviation appears after HVAC maintenance	Were filters, pressure, airflow or room recovery altered? Was exposed product protected?	Apply change-control and restoration criteria; requalification or additional monitoring may be required.
Emergency substitution required	Does the alternate differ in polymer, edge, wetting chemistry, sterility, bagging or supplier?	Conduct controlled material equivalency and risk assessment before use; document temporary controls and approval.

Do not "test until clean" as a default

Repeating tests and cleaning until an out-of-limit result passes can obscure a process that is not under control. EU Annex 15 and the FDA cleaning-validation inspection guide both emphasize predefined, scientifically supported acceptance and investigation of variability.

Product continuity is a quality-control issue

A pharmaceutical procurement checklist that avoids unqualified substitutes.

A technically excellent consumable cannot support the process if its sterile packaging, usable shelf life, lot documentation or supply continuity does not match operations. Procurement and QA should agree on critical-to-quality attributes before a shortage or late order creates pressure to substitute.

Specify

Record intended use, not just SKU

Capture the manufacturing zone and task, approved materials, chemical properties, sterility, required lot certificates, size, packaging layers and allowed alternates.

Verify

Review the latest manufacturer evidence

Check technical data sheet version, SDS, sterilization documentation, CoA/CoC where supplied, expiry, product-change notices and suitability limits.

Forecast

Plan around batch and expiry constraints

Evaluate usage by shift and campaign, sterile-release or manufacturing lead times, remaining shelf life, reorder triggers and staged deliveries.

Protect

Control substitutions before use

Compare the full material/chemistry/packaging/sterility configuration and assess any new supplier or part number under approved change control.

Trace

Retain adequate receiving records

Record manufacturer lot, received configuration, storage condition, site item code, relevant documentation and disposition or quarantine status.

Review

Use trend data to improve purchasing

Track quality complaints, user feedback, breakage, missed shelf-life windows, documented stockouts and performance of approved alternatives.

Additional resource: Sterile Procurement Planning for Cleanrooms explains the operational importance of expiry, forecasting and manufacturer lead times.

Continue learning across the Technical Vault

Connected resources for GMP operations and procurement decisions.

Related guide

Cleanroom Product Matching

Start with application and process risk to select compatible wipers, swabs, gloves and apparel.

Related guide

Solutions Matched to Wipers & Swabs

Evaluate the cleaning chemistry and application tool together, with material compatibility and sterility distinctions.

Related guide

Sporicides and Their Proper Uses

Understand spore control, actual contact times, chemistry and validated disinfection in critical environments.

Related guide

Wiper Absorbency Knowledge Base

Learn capacity, sorptive speed, liquid pickup and why absorbency is not a cleanliness rating.

Related guide

USP <797> Cleaning Solutions

Focused sterile compounding requirements and techniques. Distinct from commercial drug manufacturing.

Related guide

USP <800> Hazardous Drug Handling

Separate hazardous-drug containment, residue, PPE and exposure-control context.

Related guide

Training and How-To Guides

Practical operator education on wiping, mopping, isolators and sampling technique.

Related guide

Technical Vault — All Resources

Explore the complete SOSCleanroom technical library for controlled environments.

Pharmaceutical cleanroom FAQ

Direct answers to common manufacturing and quality questions.

Is every pharmaceutical facility required to be ISO Class 5?

No. Facility and air-control requirements depend on whether the product is sterile or nonsterile, its process and exposure risks, site quality system and applicable regulations. ISO Class 5 cannot be assigned to all manufacturing processes.

Is EU GMP Grade A identical to ISO Class 5?

Not as a complete regulatory statement. Grade A includes context for critical sterile operations, process protection and GMP monitoring; ISO 14644-1 is an airborne-particle classification standard. Similar particle limits do not make the requirements interchangeable.

What is a Contamination Control Strategy (CCS)?

For Annex 1 sterile manufacturing, a CCS is the coordinated, facility-wide system of design, procedures, technical controls and monitoring used to prevent, evaluate and improve control of contamination risks. It should be reviewed and revised where needed.

Does a sterile wiper make a surface sterile?

No. Sterile status describes the packaged wiper. Surface sterility requires separate suitable equipment, process and validated control measures. Use the correct cleaning/disinfection method and preserve sterile handling where required.

Are all 70% IPA solutions the same?

No. Products may differ in alcohol and water grades, sterile status, filtration, packaging, dispensing, documentation, expiration and substrate when pre-wetted. Exact SKU attributes must be matched to the process.

Is 70% IPA sporicidal?

No. 70% IPA is not a reliable bacterial-spore killer. Where spore control is needed, use a product with suitable verified sporicidal claims and validated application conditions.

Does Annex 1 require a new disinfectant every day?

No single universal daily alternation appears in Annex 1. It calls for a written program with more than one appropriate disinfectant type, periodic sporicidal use and validation of performance on relevant surfaces.

Can I substitute DI water for WFI in a critical cleaning method?

Only through the appropriate site qualification and change-control process. DI water, USP Purified Water and WFI carry different specifications, and sterile status is also a separate attribute.

Does a low-TOC swab automatically validate a TOC cleaning method?

No. It can support a low-background sampling method, but recovery, dilution, extraction, blank control, assay capability and sampling site must be validated for the actual equipment and residue.

How is cleaning validation different from environmental disinfection validation?

Cleaning validation of manufacturing equipment focuses on acceptable removal of API, detergent and other residues from product-contact equipment. Disinfection validation focuses on microbial efficacy of specified products and methods on designated surfaces. A program can need both.

Why does a cleanroom pass particle tests but still have viable contamination?

Airborne particle classification does not establish that microorganisms are absent from all surfaces, operators, water or materials. A robust program integrates facility design, validated disinfection, viable monitoring and investigations.

When is sterile apparel needed?

Use the garment system required by the actual process, grade and site SOP. Sterile status, performance, fit, donning, integrity, compatibility and transfer are separate selection gates; nonsterile areas may not require sterile apparel.

Does a Certificate of Conformance prove product-process compliance?

No. A supplier certificate supports the claimed attributes of a particular product or lot. The pharmaceutical manufacturer still owns site qualification, process validation, monitoring and quality disposition.

What should happen when a critical consumable is discontinued or delayed?

Do not make an undocumented substitution. Identify critical differences and obtain approved technical/quality assessment, required testing, documentation and change control before use; plan inventory and lead times proactively.

Where do USP <797> and <800> fit?

USP <797> is about compounded sterile preparations and USP <800> concerns hazardous-drug handling in healthcare settings. They do not replace FDA drug-manufacturing cGMP requirements or EU GMP Annex 1 for relevant commercial manufacturing.

Can SOSCleanroom certify a pharmaceutical cleanroom or validate a drug process?

No. SOSCleanroom supplies contamination-control consumables and product information. The manufacturer, quality unit and qualified validation specialists remain responsible for classification, supplier qualification, process validation, release and regulatory compliance.

Primary sources and official publishers

Standards and regulatory references used to frame this guide.

Use the applicable official texts and site-controlled copies when writing regulated procedures. Standards can be licensed, edition-dependent and jurisdiction-specific; these links provide publisher or regulator entry points and should not be interpreted as a legal-compliance determination.

Publisher / reference	Why it matters
21 CFR 211.42 — Design and construction	US drug manufacturing premises, segregation and aseptic areas.
21 CFR 211.67 — Equipment cleaning	Written cleaning/maintenance procedures and records.
21 CFR 211.113 — Microbiological control	Written microbial controls for sterile and nonsterile products.
21 CFR 211.180 — Records	Drug cGMP record management and quality review.
FDA Aseptic Processing Guidance (2004)	FDA guidance for sterile drug products manufactured aseptically.
FDA Guide to Inspection of Cleaning Validation	Regulatory inspection discussion of equipment residue cleaning validation.
FDA Process Validation (2011)	Lifecycle approach to drug manufacturing process validation.
ICH Q9(R1) Quality Risk Management (2023)	Formal quality risk management principles, methods and subjectivity control.
FDA Data Integrity and Compliance With Drug CGMP (2018)	Reliable and accurate data and risk-based data integrity controls.
European Commission — EudraLex Volume 4	Official current listing of EU GMP requirements and annexes.
EU GMP Annex 1 (2022 revision)	Sterile manufacturing CCS, grades, disinfection, operations and monitoring; fully applicable 25 August 2024.
EU GMP Annex 15 (2015)	Qualification and validation, including section 10 on cleaning validation.
ISO 14644-1:2015	Airborne-particle classification of cleanrooms.
ISO 14644-5:2025	Operations Control Program; revised 2025 edition.
ISO 14644-18:2023	Cleanroom consumable suitability assessment framework.
USP General Chapter <797>	Defined scope and requirements for sterile compounding.
USP General Chapter <800>	Defined scope and standards for healthcare hazardous-drug handling.

SOSCLEANROOM | PHARMACEUTICAL CONTAMINATION-CONTROL SUPPLIES

Standardize Approved Cleanroom Consumables Without Compromising Your Quality System.

Have an approved product list, sterile supply specification, cleaning-validation swab requirement, disinfectant rotation program or critical material substitution to evaluate? Send the manufacturer part numbers, process use, packaging/sterility requirements, desired lot documentation, approximate usage and delivery needs. SOScleanroom can help identify catalog options and purchasing continuity while your site retains technical and regulatory approval authority.

Request a Quote → Explore Purchasing Programs →

Questions? 800-443-7101

Educational scope and source review: October 27, 2026. This guide is not an approved GMP procedure, aseptic-process validation, legal opinion, ISO facility classification, independent product qualification or a representation that SOScleanroom performs testing/certification services. The responsible manufacturer, quality unit and applicable regulatory authorities determine actual specifications, standard editions, validation, data integrity, sterility, personal safety, product release and authorized substitutions. Product characteristics, manufacturer documents and availability can change; consult the latest documentation.